Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models

Core Insights - Erasca Inc. (NASDAQ:ERAS) is experiencing a rise in stock price targets from multiple investment firms due to recent clinical developments and updated financial models [1][2][3] Group 1: Price Target Increases - Guggenheim raised its price target for Erasca from $5 to $12, maintaining a Buy rating, based on updated clinical developments and financing [1] - Morgan Stanley increased its price target from $4 to $10 while keeping an Equal Weight rating, following promising initial clinical data for ERAS-0015 [2] - Piper Sandler raised its price target from $5 to $11 with an Overweight rating, reflecting updates from its Catalyst Tracker and valuation models [3] Group 2: Clinical Developments - The revised valuation by Guggenheim includes risk-adjusted revenue estimates for ERAS-0015, with a 30% probability of success in treating second-line or later non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [1] - Morgan Stanley noted two confirmed and one unconfirmed partial response at the 8 mg QD dose level for ERAS-0015, leading to an increase in probability-of-success estimates [2] Group 3: Company Overview - Erasca Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers [4]